

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

BFAR RABBIT PAB

货号: S220103 产品全名: BFAR 兔多抗 基因符号 BAR; RNF47

UNIPROT ID: Q9NZS9 (Gene Accession - NP_057645)

背景: A novel protein, BAR, for bifunctional apoptosis regulator, contains domains that enable it to interact with components of both major apoptosis pathways, where it negatively regulates apoptotic signaling. Like the other anti-apoptosis proteins Bap31 and FLIP, BAR contains a DED-like domain that is capable of suppressing apoptosis mediated at the receptor level. In addition, BAR contains a domain that also enables it to interact with the mitochondrial Bcl-2 family of proteins. The presence of these various RING, SAM, DED and TM domains suggests that BAR may serve as a scaffold protein that integrates signaling components of the cells apoptosis-regulatory machinery.

抗原: Synthetic peptide of human BFAR

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 25-100; ELISA: 1000-2000

种属反应性: Rabbit 克隆性: Rabbit Polyclonal


亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Cancer


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 220103(BFAR Antibody) at a dilution of 1/20(Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 220103(Anti-BFAR Antibody) at dilution 1/20.



The image on the left is immunohistochemistry of paraffinembedded Human gastric cancer tissue using 220103(Anti-BFAR Antibody) at a dilution of 1/20.



In comparision with the IHC on the left, the same paraffin-embedded Human gastric cancer tissue is first treated with synthetic peptide and then with D260960(Anti-BFAR Antibody) at dilution 1/20.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010